| HOME >> BIOLOGY >> TECHNOLOGY |
- Original research to quantify the full extent of residual
vascular risk in patients with atherogenic dyslipidemia and to identify
new targets for interventions.
- Educational programs to create awareness of residual vascular
risk and to encourage healthcare professionals, particularly Primary
Care Physicians (PCPs), to translate available research findings into
improved treatment strategies.
- Advocacy to ensure that the issue of residual vascular risk
associated with atherogenic dyslipidemia is given appropriate priority
in national and international guidelines.
"Our overall goal must be to provide knowledge and understanding to allow physicians to get closer to normalizing residual vascular risk in patients with heart disease and/or diabetes," Frank Sacks, Professor of Cardiovascular Disease Prevention, Harvard School of Public Health, Professor of Medicine, Harvard Medical School, Boston, USA and Vice-president of R3i, said. "We hope that the original research conducted under the auspices of R3i and the widespread communication of current knowledge and new data will lead to significant improvements in the reduction of risk beyond the levels we achieve now. Despite significant advances in reducing vascular risk in the last 20 years, we have only just begun to address this issue. We invite our colleagues to join us in addressing this important challenge."
The R3i is led by a Board of Trustees and an International Steering
Committee (ISC) of 21 officers and members from the disciplines of
cardiology, diabetology, lipidology, endocrinology, epidemiology,
nutrition, ophthalmology, nephrology and basic science. The legal body of
the R3i will be a Foundation established in Switzerland. National
organizat
'/>"/>
| SOURCE Residual Risk Reduction Initiative (R3i) Copyright©2008 PR Newswire. All rights reserved |